Earlybrite

Earlybrite company information, Employees & Contact Information

Explore related pages

Related company profiles:

An innovative Edtech platform with a focus to upskill the knowledge of the next generation through shared learning and hands-on activities 🤖 👨🚀👩🔧🕵♂️🧑💻🛰🚀

Company Details

Employees
21
Founded
-
Address
Lekki, Lagos 234, Ng
Industry
E-Learning Providers
Keywords
IT Consulting.
HQ
Lekki, Lagos
Looking for a particular Earlybrite employee's phone or email?

Earlybrite Questions

News

Warner Bros. Discovery to be split, as Zaslav retreats from grand ambitions - NPR

Warner Bros. Discovery to be split, as Zaslav retreats from grand ambitions NPR

Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis - ACS Publications

Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis ACS Publications

Black Hill Discovery Center - Montgomery Parks

Black Hill Discovery Center Montgomery Parks

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials - Frontiers

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials Frontiers

Shark Conservation is Essential to Tackle Climate Change - discovery.com

Shark Conservation is Essential to Tackle Climate Change discovery.com

Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery - Nature

Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery Nature

David Zaslav’s Warner Bros. Discovery Empire Takes Shape: Less Red Tape, More “Accountability” - The Hollywood Reporter

David Zaslav’s Warner Bros. Discovery Empire Takes Shape: Less Red Tape, More “Accountability” The Hollywood Reporter

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279 | Journal of Medicinal Chemistry - ACS Publications

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279 | Journal of Medicinal Chemistry ACS Publications

Kinase drug discovery 20 years after imatinib: progress and future directions - Nature

Kinase drug discovery 20 years after imatinib: progress and future directions Nature

Machine Learning for Discovery of New ADORA Modulators - Frontiers

Machine Learning for Discovery of New ADORA Modulators Frontiers

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis - ACS Publications

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis ACS Publications

Discovery of Biologically Optimized Polymyxin Derivatives Facilitated by Peptide Scanning and In Situ Screening Chemistry - ACS Publications

Discovery of Biologically Optimized Polymyxin Derivatives Facilitated by Peptide Scanning and In Situ Screening Chemistry ACS Publications

Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation - ACS Publications

Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation ACS Publications

The Chosen Few: Parallel Library Reaction Methodologies for Drug Discovery - ACS Publications

The Chosen Few: Parallel Library Reaction Methodologies for Drug Discovery ACS Publications

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 - ACS Publications

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 ACS Publications

SmartCADD: AI-QM Empowered Drug Discovery Platform with Explainability - ACS Publications

SmartCADD: AI-QM Empowered Drug Discovery Platform with Explainability ACS Publications

Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator - ACS Publications

Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator ACS Publications

Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma - ACS Publications

Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma ACS Publications

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? - ACS Publications

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? ACS Publications

Discovery and Hit to Lead Optimization of Macrocyclic Peptides as Novel Tropomyosin Receptor Kinase A Antagonists - ACS Publications

Discovery and Hit to Lead Optimization of Macrocyclic Peptides as Novel Tropomyosin Receptor Kinase A Antagonists ACS Publications

Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2 | Communications Biology - Nature

Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2 | Communications Biology Nature

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma - ACS Publications

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma ACS Publications

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase - ACS Publications

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase ACS Publications

Structure-guided discovery of a single-domain antibody agonist against human apelin receptor - Science | AAAS

Structure-guided discovery of a single-domain antibody agonist against human apelin receptor Science | AAAS

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties - ACS Publications

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties ACS Publications

Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy - ScienceDirect.com

Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy ScienceDirect.com

Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors - ACS Publications

Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors ACS Publications

Discovery and characterization of bromodomain 2–specific inhibitors of BRDT - PNAS

Discovery and characterization of bromodomain 2–specific inhibitors of BRDT PNAS

Warner Bros. Discovery CEO David Zaslav has remade the leadership of CNN, DC, and the company's legendary film studio — here are the 105 executives driving his strategy now - businessinsider.com

Warner Bros. Discovery CEO David Zaslav has remade the leadership of CNN, DC, and the company's legendary film studio — here are the 105 executives driving his strategy now businessinsider.com

Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor - ACS Publications

Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor ACS Publications

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition - ACS Publications

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition ACS Publications

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors - ACS Publications

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors ACS Publications

MS Discovery Forum to Suspend Publication - msdiscovery.org

MS Discovery Forum to Suspend Publication msdiscovery.org

“No great discovery was ever made without a bold guess,” Sir Isaac Newton - msdiscovery.org

“No great discovery was ever made without a bold guess,” Sir Isaac Newton msdiscovery.org

Warner Bros Discovery Merger: Who’s In, Who’s Out In The Executive Ranks - Deadline

Warner Bros Discovery Merger: Who’s In, Who’s Out In The Executive Ranks Deadline

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate - ACS Publications

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate ACS Publications

The Oligodendrocyte Whisperer - msdiscovery.org

The Oligodendrocyte Whisperer msdiscovery.org

Analysis of the Discovery Institute's Bibliography - National Center for Science Education (NCSE)

Analysis of the Discovery Institute's Bibliography National Center for Science Education (NCSE)

Rare Family Cluster of MS Reveals New Clues - msdiscovery.org

Rare Family Cluster of MS Reveals New Clues msdiscovery.org

More Than Meets the Eye - msdiscovery.org

More Than Meets the Eye msdiscovery.org

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant